Cargando…

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Castleman’s disease (CD) is a rare lymphoproliferative disorder, and its prevalence in Thailand is not known. This 10-year period study investigated the prevalence of CD in Thailand, and the clinical characteristics and outcomes of Thai CD patients, with special focus on the existence and prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Owattanapanich, Weerapat, Pholmoo, Wikanda, Pongpruttipan, Tawatchai, Siritanaratkul, Noppadol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910486/
https://www.ncbi.nlm.nih.gov/pubmed/29464312
http://dx.doi.org/10.1007/s00277-018-3269-x
_version_ 1783316057095667712
author Owattanapanich, Weerapat
Pholmoo, Wikanda
Pongpruttipan, Tawatchai
Siritanaratkul, Noppadol
author_facet Owattanapanich, Weerapat
Pholmoo, Wikanda
Pongpruttipan, Tawatchai
Siritanaratkul, Noppadol
author_sort Owattanapanich, Weerapat
collection PubMed
description Castleman’s disease (CD) is a rare lymphoproliferative disorder, and its prevalence in Thailand is not known. This 10-year period study investigated the prevalence of CD in Thailand, and the clinical characteristics and outcomes of Thai CD patients, with special focus on the existence and prevalence of TAFRO syndrome. TAFRO syndrome is defined as CD with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Thirty-three CD patients diagnosed and treated at Siriraj Hospital during January 2007 to December 2016 were included. The prevalence of CD was 1.4 per 1,000,000 patients/10 years. Median age was 46 years, with slight female predominance. Six patients were assigned to the TAFRO group. A high proportion of TAFRO syndrome (18.2%) was found among Thai adult CD patients. In addition to routine TAFRO diagnostic criteria, significantly lower hemoglobin and albumin levels were observed in the TAFRO group than in the non-TAFRO group. Treatment outcomes of CD patients were complete remission (52%), stable disease (30%), and death (13%). Three-year overall survival in the non-TAFRO group and TAFRO group was 88 and 50%, respectively. While most CD patients had a good prognosis, severe cases with TAFRO syndrome had poor outcome.
format Online
Article
Text
id pubmed-5910486
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59104862018-04-24 High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience Owattanapanich, Weerapat Pholmoo, Wikanda Pongpruttipan, Tawatchai Siritanaratkul, Noppadol Ann Hematol Original Article Castleman’s disease (CD) is a rare lymphoproliferative disorder, and its prevalence in Thailand is not known. This 10-year period study investigated the prevalence of CD in Thailand, and the clinical characteristics and outcomes of Thai CD patients, with special focus on the existence and prevalence of TAFRO syndrome. TAFRO syndrome is defined as CD with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Thirty-three CD patients diagnosed and treated at Siriraj Hospital during January 2007 to December 2016 were included. The prevalence of CD was 1.4 per 1,000,000 patients/10 years. Median age was 46 years, with slight female predominance. Six patients were assigned to the TAFRO group. A high proportion of TAFRO syndrome (18.2%) was found among Thai adult CD patients. In addition to routine TAFRO diagnostic criteria, significantly lower hemoglobin and albumin levels were observed in the TAFRO group than in the non-TAFRO group. Treatment outcomes of CD patients were complete remission (52%), stable disease (30%), and death (13%). Three-year overall survival in the non-TAFRO group and TAFRO group was 88 and 50%, respectively. While most CD patients had a good prognosis, severe cases with TAFRO syndrome had poor outcome. Springer Berlin Heidelberg 2018-02-20 2018 /pmc/articles/PMC5910486/ /pubmed/29464312 http://dx.doi.org/10.1007/s00277-018-3269-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Owattanapanich, Weerapat
Pholmoo, Wikanda
Pongpruttipan, Tawatchai
Siritanaratkul, Noppadol
High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title_full High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title_fullStr High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title_full_unstemmed High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title_short High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
title_sort high proportion of tafro syndrome in thai adult castleman’s disease patients: a 10-year experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910486/
https://www.ncbi.nlm.nih.gov/pubmed/29464312
http://dx.doi.org/10.1007/s00277-018-3269-x
work_keys_str_mv AT owattanapanichweerapat highproportionoftafrosyndromeinthaiadultcastlemansdiseasepatientsa10yearexperience
AT pholmoowikanda highproportionoftafrosyndromeinthaiadultcastlemansdiseasepatientsa10yearexperience
AT pongpruttipantawatchai highproportionoftafrosyndromeinthaiadultcastlemansdiseasepatientsa10yearexperience
AT siritanaratkulnoppadol highproportionoftafrosyndromeinthaiadultcastlemansdiseasepatientsa10yearexperience